Verition Fund Management LLC Sells 9,000 Shares of Immutep Limited (NASDAQ:IMMP)

Verition Fund Management LLC lowered its holdings in shares of Immutep Limited (NASDAQ:IMMP) by 25.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,000 shares of the biotechnology company’s stock after selling 9,000 shares during the period. Verition Fund Management LLC’s holdings in Immutep were worth $57,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in shares of Immutep during the second quarter valued at approximately $26,000. XY Capital Ltd acquired a new stake in Immutep in the 2nd quarter valued at $105,000. Finally, Meridian Wealth Management LLC increased its stake in Immutep by 4.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after purchasing an additional 17,250 shares in the last quarter. 2.32% of the stock is currently owned by institutional investors.

Immutep Stock Up 2.4 %

Shares of Immutep stock opened at $2.13 on Wednesday. Immutep Limited has a 52 week low of $1.66 and a 52 week high of $3.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25. The business has a 50 day moving average price of $1.99 and a 200-day moving average price of $2.18.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird lifted their price objective on shares of Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, November 15th.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.